City of Hope is a recognized leader in myelodysplasia research with more than three decades of experience. Our research projects have been funded by the National Cancer Institute (NCI) and many other research-based organizations, and our scientists collaborate with other leading research institutions to develop tomorrow’s breakthroughs today.
City of Hope is studying methods to minimize risk and severity of graft-versus-host disease (GvHD) for myelodysplasia patients who had undergone an allogeneic stem cell transplant, including use of immunosuppressants and developing a better process of matching donors to recipients.
Developing a safe and effective stem cell transplantation protocol for HIV-positive patients with myelodysplastic syndrome.
Investigating the biological mechanisms that transform myelodysplasia into leukemia and how those processes can be halted.
Looking into ways to minimize risk of developing secondary myelodysplastic syndrome resulting from current cancer treatments.
If you have been diagnosed with a myelodysplastic syndrome disorder or are looking for a second opinion consultation about your treatment, find out more about
becoming a patient
or contact us at 800-826-HOPE.